Turkish Journal of Medical Sciences
Volume 32

Number 1

Article 14

1-1-2002

A Rare Case of Neonatal Hypotonia: Neonatal Nonketotic
Hyperglycinemia
AYHAN TAŞTEKİN
RAHMİ ÖRS
BEHZAT ÖZKAN
ORHAN DENİZ

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
TAŞTEKİN, AYHAN; ÖRS, RAHMİ; ÖZKAN, BEHZAT; and DENİZ, ORHAN (2002) "A Rare Case of Neonatal
Hypotonia: Neonatal Nonketotic Hyperglycinemia," Turkish Journal of Medical Sciences: Vol. 32: No. 1,
Article 14. Available at: https://journals.tubitak.gov.tr/medical/vol32/iss1/14

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turk J Med Sci
32 (2002) 73-75
© TÜB‹TAK

Short Report
1

Ayhan TAfiTEK‹N
1
Rahmi ÖRS
2
Behzat ÖZKAN
3
Orhan DEN‹Z

A Rare Case of Neonatal Hypotonia: Neonatal Nonketotic Hyperglycinemia

Received: July 07, 2001

Abstract: Hypotonia is a serious physical
finding in a newborn infant. Nonketotic
hyperglycinemia (NKH) is a rare cause of
neonatal hypotonia. It is a defect of the
glycine metabolism and has poor prognosis.
We report a case of a newborn infant with
NKH, presented with mild hypotonia and high
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Introduction
Hypotonia, central or peripheral, is a serious physical
finding in a newborn infant. There are many disorders
that cause hypotonia. It may arise from disorders of the
brain, spinal cord, peripheral nervous system and motor
unit. Inborn errors of the metabolism may also cause
hypotonia. Nonketotic hyperglycinemia (NKH) is an
inborn error of glycine degradation, which causes hypotonia, lethargy, apnea, seizures, and hiccups (1, 2). Its
frequency is lower than 1 in 200,000 and most of the
patients die during the neonatal period. Özalp et al.
reported that the prevalence of NKH was 0.04% in 6050
high-risk infants for metabolic disease in Turkey (3). We
report a newborn infant with NKH as a rare cause of
neonatal hypotonia.

Patient Report
A 24-hour old female infant was admitted to our unit
with mild hypotonia. She had a history of sibling death.
The infant was born at term to a 25-year-old woman, following an uncomplicated pregnancy. The parents noted
her to be hypotonic with poor feeding and crying immediately after delivery similar to the sibling that died at 20
days of age two years previously. There was no parental
consanguinity.
Her weight, length and head circumference were
3300 g, 51 cm and 35 cm, respectively. No abnormal
physical findings were determined except hypotonia and

creatine kinase values. NKH should be
considered in a hypotonic newborn, especially
if associated with acute deterioration,
lethargy and seizures.
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poor sucking. A sepsis work-up was performed and
antibiotics were administered. On the 2nd hospital day, the
patient deteriorated acutely, and she was intubated and
placed on mechanical ventilation because of impending
respiratory failure. Respiratory alkalosis improved after
ventilatory support. Within five days, two serial blood cultures showed Candida lipolytica, and amphotericin B was
administered.
Blood urea nitrogen, creatinine, aspartate transaminase, alanin transaminase, serum glucose and electrolytes
were normal. Serum thyroid hormone levels were also
normal. The serum creatine kinase (CK) level was 1883
U/L (normal serum level is 87-725 U/L at 72-100 h of
life). The plasma ammonium level was 203 µg/L (normal
serum level is 15-90 µg/L), but this subsided within 72
hours. The blood lactate level was normal. Cranial ultrasonography and echocardiography did not show any
abnormality. Computed tomography (CT) revealed an
arachnoid cyst in the occipital area.
In the following days, the infant developed generalized seizures and hiccups, and hypotonia became severe
and was thought to be permanent. The frequency and
duration of the convulsions decreased with phenobarbital
treatment. High CK values (1883-923-387 U/L, respectively) decreased to normal within 2 weeks. Electromyography (EMG) and muscle biopsy were evaluated as normal. Electroencephalography (EEG) showed a burst suppression pattern. Serum and CSF glycine were 1449 and
224 mumol/L, respectively. (Normal serum level is 104-
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254 mumol/L and CSF level is 5+/-2 mumol/L). The
CSF/serum ratio of glycine was 0.15 (a value of greater
than 0.08 is diagnostic).
The patient was diagnosed as having NKH, and sodium benzoate (500 mg/kg/day) and folic acid treatment
was started with protein restriction. This treatment regimen resulted in cessation of seizure activity, so phenobarbital medication was stopped. But lethargy and hypotonia continued. The patient was weaned off the ventilator at 47 days of age, but did not tolerate gavage feeding well. Different antibiotics were administered such as
vancomycin, meropenem and amikacin, due to bronchopneumonia and sepsis.
The patient died at the end of 4 months of age
because of bronchopneumonia caused by Pseudomonas
aeruginosa that was resistant to multiple drugs.

Discussion
Nonketotic hyperglycinemia, classified as neonatal,
infantile, late onset and transient based on its clinical
course, is a very rare autosomal recessively inherited disease. The metabolic defect of NKH is in the glycine cleavage system (GCS), a complex enzyme system with four
components: the P, the H, the T, and the L protein (4).
Most patients with the neonatal type have a defect in the
P protein. Later-onset cases have been thought to have
defects in the H or T protein. Due to deficient activity of
the GCS, the major pathway for the catabolism of glycine,
large quantities of glycine accumulate in all body tissues.
High concentrations of glycine in the central nervous system produce excitoneurotoxicity, seizure and brain damage, through the overstimulation of the N-methyl-Daspartic acid (NMDA) receptor, via an action at the associated glycine modulatory site (4). Otherwise, glycine is
inhibitory in the spinal cord and brain stem and this may
be responsible for the apnea seen in the disease.
Most patients have the neonatal type characterized by
lethargy, hypotonia and poor sucking in the first few days
of life, while the infants are usually well at birth.
Encephalopathy progresses to coma and most patients
require assisted ventilation and die in the neonatal period.
The patients who survive develop intractable seizures and
mental retardation. Hiccups may be seen because of
diaphragmatic spasms. The presenting features of our
patient suggested spinal muscular atrophy (SMA) or an

74

inborn error of metabolism. As the patient was not alert,
tongue fasciculation was absent and specific EMG findings
related to Werdnig-Hoffman were not recorded, SMA
was ruled out.
The main laboratory finding in NKH is elevation of
glycine in serum, urine and CSF. A value of greater than
0.08 in the CSF/serum glycine concentration ratio is diagnostic. The serum and CSF glycine levels in our patient
were diagnostic for NKH. Liver GCS activity is indicated to
determine the severity of the disease and for prenatal
diagnosis. We were unable to measure GCS activity in our
patient due to technical limitations. Carnitine deficiency
(5) and transient hyperammoniemia (6) have been
reported in some cases. We detected high CK values in
our patient, which have never been reported previously.
We suggested that the elevated level of serum CK was
due to undocumented perinatal asphyxia in this patient.
Even though hypotonia persisted, the CK level decreased
to normal after the second week of life.
Agenesis or hypoplasia of the corpus callosum is a
characteristic finding of the disease but not diagnostic.
Delayed myelination of the cerebral white matter has
been reported in most cases of NKH. Gyral malformation,
ventricular enlargement, cerebellar hypoplasia (7) and
intracranial hemorrhage (6) and hydrocephalus (8) have
been described in some cases. There was no abnormality
on CT except the arachnoid cyst in our patient. Magnetic
resonance (MR) examination is the imaging modality of
choice for NKH because it can demonstrate the degree of
myelination.
A burst-suppression pattern seen on our patient’s EEG
is not diagnostic of NKH but is highly suggestive, since its
most common cause is NKH.
There is no effective treatment. Therapy strategies
are directed to decrease the glycine concentration (sodium benzoate) and NMDA receptor antagonization (dextromethorphan and ketamine). While some investigators
reported improvement (5,6), others saw no clinical
response (9). Seizures in NKH may be controlled with
only sodium benzoate and/or dextromethorphan (10,11).
But for some patients, it is required to use additional anticonvulsant therapy such as phenobarbital, diazepam-a
competitor for glycine receptors, or felbamate (10). In
our patient, seizures disappeared with sodium benzoate
therapy and did not recur after the discontinuation of
phenobarbital medication.

A. TAfiTEK‹N, R. ÖRS, B. ÖZKAN, O. DEN‹Z

In conclusion, NKH is a rare cause of neonatal hypotonia without consistently effective treatment and should
be considered in a hypotonic newborn, especially if associated with lethargy and seizure, and acute deterioration
of an infant that seems relatively well after delivery. The
recognition of this metabolic disorder as the cause has
important implications not only for the immediate care of
the patient, but also for genetic counseling in order to
prevent recurrences in further pregnancies. Also we
would like to draw attention to the fact that neonatal central hypotonia associated with elevated serum CK activity
should be followed up before the final diagnosis has been
established.
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